ICO6 Rec'd PCT/PIU

ORM PTO-1390 (Modified) REV. 2-2005) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE

## TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER

PB60228USw

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/553878

INTERNATIONAL APPLICATION NO. PRIORITY DATE CLAIMED INTERNATIONAL FILING DATE PCT/EP2004/004244 April 21, 2004 April 23, 2003 TITLE OF INVENTION TRICYCLIC INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE APPLICANT(S) FOR DO/EO/US Emmanuel Hubert DEMONT, Sally REDSHAW, Daryl Simon WALTER Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. × This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 2.  $\boxtimes$ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), 3. (9) and (24) indicated below.  $\boxtimes$ The US has been elected (Article 31). 4. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) 5. is attached hereto (required only if not communicated by the International Bureau). b. 🛛 has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). b. □ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))  $\boxtimes$ 7. a. 🔲 are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. b. 🗆 have not been made; however, the time limit for making such amendments has NOT expired. c. 🔲 d. 🛛 have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 8. An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).  $\boxtimes$ 9. An English language translation of the annexes to the International Preliminary Examination Report under PCT 10. Article 36 (35 U.S.C. 371 (c)(5)). A copy of the International Preliminary Examination Report (PCT/IPEA/409).  $\boxtimes$ 11.  $\boxtimes$ A copy of the International Search Report (PCT/ISA/210). 12 Items 13 to 23 below concern document(s) or information included:  $\boxtimes$ An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 13. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 14. 15. Ø A FIRST preliminary amendment. 16. A SECOND or SUBSEQUENT preliminary amendment. 17. A substitute specification. A power of attorney and/or change of address letter. 18. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 19. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 20. 21. A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).  $\boxtimes$ 22. Express Mail Label No. EV332065831US 23.  $\boxtimes$ Other items or information: Copy of PCT publication coverpage; Copy of PCT Request

## JE20 Rec'd PET/PTO 1/ UUI Zuus

PTO-1390 (Rev. 02-2005)

Approved for use through 3/31/2007. OMB 0851-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE equired to respond to a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a conecutor of information							it discos it displays a valid	Ciril Control Humber:	
U.S. APPLICATION NO (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO. PCT/EP2004/004244							ATTORNEY'S DOCKET NUMBER  PB60228USw		
						CALCULATIONS	PTO USE		
The following fees are submitted:								r	
24. Basic national fee							\$ \$300.00		
25.  Examination fee  If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)							\$ \$200.00		
26. Search fee  Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority							\$ \$400.00		
TOTAL OF 24, 25 and 26 =							\$ \$900.00		
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.									
Total Sheets	Extra Sheets	Num	each additional 50 of (round up to a wh	or	RATE				
71 - 100 =	0 /50 =					× \$250.00	\$ \$0.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).							\$		
CLAIMS	NUMBER F	ILED	NUMBER EXTRA		RATE				
Total claims	14	14 - 20 =		0	x	\$50.00	\$ \$0.00		
Independent clair	ns 1	- 3=		0	×	\$200.00	\$ \$0.00		
MULTIPLE DEPENDENT CLAIMS (if applicable) □ + \$360.00							\$ \$0.00		
TOTAL OF ABOVE CALCULATIONS =							\$ \$900.00		
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.							\$ \$0.00		
SUBTOTAL =							\$ \$900.00		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).							\$ \$0.00		
TOTAL NATIONAL FEE =							\$ \$900.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +							\$ \$0.00		
TOTAL FEES ENCLOSED =							\$ \$900.00		
							Amount to be	\$	
							Amount to be	\$	
a. A check in the amount of \$ to cover the above fees is enclosed.									
b. Please charge my Deposit Account No. 07-1392 in the amount of \$900.00 to cover the above fe A duplicate copy of this sheet is enclosed.									
c. The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 07-1392 . A duplicate copy of this sheet is enclosed.									
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.									
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.									
SEND ALL CORRESPONDENCE TO:  SIGNATURE SIGNATURE							L. Depperbrock		
							Deppenbrock		
REGISTRA*							TION NUMBER		

<u> JC20 Rec'd PCT/PTO 17 0C</u>T 2005

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)** Docket No. oplicant(s): DEMONT et al. PB60228USw Filing Date Examiner Customer No. **Group Art Unit** 23347

TRICYCLIC INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER'S

I hereby certify that the following correspondence:

Submission under 35 USC 371 including a copy of the IPER and ISR, Declaration, Preliminary Amendment, DS-1449, 16 references, a copy of the PCT publication coverpage, and a copy of the PCT Request

(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Ucf. 17, 2005

**Patty Wilson** (Typed or Printed Name of Person Mailing Correspondence) e of Person Mailing Correspondence) EV332065831US ("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing.

P06A/REV03